Dr. Charles Vega and Dr. Michael Simon Discuss a Case Involving a High-Risk Patient With Influenza

Provider Statement: This continuing education activity is provided by .

Support Statement: This activity is supported by an educational grant from Genentech, Inc.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Activity Description

While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving treatment effectiveness, especially in pediatric and adolescent patients. In this podcast series, expert clinicians will discuss the latest evidence regarding the use of antiviral agents for the treatment of patients with influenza who are at normal or high risk for complications and the use of antiviral agents for influenza treatment based on their efficacy and ability to reduce the transmission of the disease.

Target Audience: The intended audience for this activity is pediatric nurse practitioners and other health care professionals involved in the management of patients with influenza.

Learning Objective: Upon successful completion of this activity, participants should be better able apply the latest evidence into practice regarding the use of antiviral agents for the treatment of patients with influenza who are at normal or high risk for complications.

Activity Chair:
Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor, Department of Family Medicine
Executive Director, Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA

Faculty
Michael W. Simon, MD, PhD, AAP
Clinical Professor of Pediatrics
University of Kentucky
Lexington, KY

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Barbara A. Niedz, PhD, RN, CPHQ
Chad Rittle, DNP, MPH, RN, FAAOHN

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

This enduring material is approved for 1 year from the date of original release, August 31, 2020, to August 30, 2021.

How to Participate in This Activity and Obtain CME Credit:
To participate in this CE activity, you must read the objective, answer the pretest question, listen to the podcast, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hours Certificate.

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Chair and Faculty report the following relationship(s):
Charles P. Vega, MD, FAAFP
No relevant financial relationships to disclose.

Michael W.Simon, MD, PhD
Speakers Bureau: Genentech/Roche
Contracted Research: Abbott Medical Optics, Allergan, AstraZeneca/Medimmune, Incyte, Merck, Pfizer, Sanofi Pasteur

Reviewers report the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Chad Rittle, DNP, MPH, RN, FAAOHN
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this CME activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at cme@vindicoCME.com